Table 1.
Patient treatments and responses.
| Patient ID | Age (years) | Sex | Smoking | Histopathologic type | Response | CNV score | Pre-treatment | Treatment | Lines of treatment |
|---|---|---|---|---|---|---|---|---|---|
| P01 | 60 | F | N | A | SD | 0.027 | Chemo + anti-angiogenesis | IO | 2 |
| P02 | 66 | M | Y | S | PR | 0.028 | Chemo + RT | IO | 2 |
| P03 | 59 | M | Y | S | SD | 0.031 | Chemo + RT | IO | 2 |
| P04 | 70 | F | N | A | PD | 0.034 | Chemo | IO | 2 |
| P05 | 65 | M | Y | A | PR | 0.042 | Chemo | IO | 2 |
| P06 | 69 | M | Y | S | PR | 0.043 | Chemo + anti-angiogenesis | IO | 2 |
| P07 | 59 | F | N | A | SD | 0.050 | Chemo | IO | 2 |
| P08 | 74 | M | Y | A | SD | 0.051 | Chemo + anti-angiogenesis | IO | 2 |
| P09 | 61 | F | Y | S | SD | 0.052 | Chemo | IO + chemo | 2 |
| P10 | 60 | M | N | S | SD | 0.059 | Chemo | IO | 3 |
| P11 | 58 | M | Y | S | PR | 0.065 | Chemo | IO + chemo | 2 |
| P12 | 55 | F | N | A | SD | 0.067 | Chemo | IO | 2 |
| P13 | 59 | F | N | A | PR | 0.072 | TKI | IO | 3 |
| P14 | 60 | M | Y | A | SD | 0.078 | Chemo | IO + chemo | 2 |
| P15 | 63 | M | Y | A | PR | 0.084 | Chemo | IO + chemo | 2 |
| P16 | 67 | M | Y | S | PR | 0.089 | Chemo | IO + chemo | 2 |
| P17 | 60 | M | Y | A | PR | 0.090 | Chemo | IO + chemo | 2 |
| P18 | 55 | M | Y | A | PD | 0.101 | Chemo | IO | 2 |
| P19 | 46 | M | Y | S | SD | 0.109 | Chemo + RT | IO | 2 |
| P20 | 74 | M | Y | S | SD | 0.113 | Chemo | IO | 2 |
| P21 | 54 | M | Y | A | PR | 0.122 | Chemo | IO + chemo | 2 |
| P22 | 62 | M | Y | S | SD | 0.142 | Chemo | IO | 2 |
| P23 | 52 | M | Y | S | PD | 0.418 | Chemo | IO | 2 |
| P24 | 60 | F | N | A | PD | 0.538 | Chemo | IO | 2 |
| P25 | 66 | M | Y | S | PD | 30.248 | Chemo + RT | IO | 2 |
M: male; F: female; A: adenocarcinoma; S: Squamous carcinoma; PD: progressive disease; PR: partial response; SD: stable disease; CR: complete response; PFS: progression-free survival; CNV: copy number variation; IO: PD1/PD-L1 immunotherapy; chemo: chemotherapy; RT: radiotherapy.